Skip to main content

Peer Review reports

From: Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials

Original Submission
7 May 2024 Submitted Original manuscript
2 Jul 2024 Reviewed Reviewer Report
4 Jul 2024 Reviewed Reviewer Report
5 Jul 2024 Reviewed Reviewer Report
8 Aug 2024 Author responded Author comments - Yazan A. Al-Ajlouni
Resubmission - Version 2
8 Aug 2024 Submitted Manuscript version 2
Publishing
16 Aug 2024 Editorially accepted
27 Sep 2024 Article published 10.1186/s12882-024-03713-9

You can find further information about peer review here.

Back to article page